Edoxaban in the secondary prevention of VTE.
Publication
, Journal Article
Levy, JH; Hunt, BJ
Published in: Lancet Haematol
May 2016
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Lancet Haematol
DOI
EISSN
2352-3026
Publication Date
May 2016
Volume
3
Issue
5
Start / End Page
e208 / e209
Location
England
Related Subject Headings
- Venous Thromboembolism
- Thiazoles
- Secondary Prevention
- Pyridines
- Humans
- Anticoagulants
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Levy, J. H., & Hunt, B. J. (2016). Edoxaban in the secondary prevention of VTE. Lancet Haematol, 3(5), e208–e209. https://doi.org/10.1016/S2352-3026(16)00037-5
Levy, Jerrold H., and Beverley J. Hunt. “Edoxaban in the secondary prevention of VTE.” Lancet Haematol 3, no. 5 (May 2016): e208–9. https://doi.org/10.1016/S2352-3026(16)00037-5.
Levy JH, Hunt BJ. Edoxaban in the secondary prevention of VTE. Lancet Haematol. 2016 May;3(5):e208–9.
Levy, Jerrold H., and Beverley J. Hunt. “Edoxaban in the secondary prevention of VTE.” Lancet Haematol, vol. 3, no. 5, May 2016, pp. e208–09. Pubmed, doi:10.1016/S2352-3026(16)00037-5.
Levy JH, Hunt BJ. Edoxaban in the secondary prevention of VTE. Lancet Haematol. 2016 May;3(5):e208–e209.
Published In
Lancet Haematol
DOI
EISSN
2352-3026
Publication Date
May 2016
Volume
3
Issue
5
Start / End Page
e208 / e209
Location
England
Related Subject Headings
- Venous Thromboembolism
- Thiazoles
- Secondary Prevention
- Pyridines
- Humans
- Anticoagulants
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology